 Neuroprotective Agents
"Neuroprotective Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
| Descriptor ID |
D018696
|
| MeSH Number(s) |
D27.505.696.706.548 D27.505.954.427.575
|
| Concept/Terms |
Neuroprotective Agents- Neuroprotective Agents
- Agents, Neuroprotective
- Neuroprotectants
- Neuroprotective Drugs
- Drugs, Neuroprotective
Neuroprotective Effect- Neuroprotective Effect
- Effect, Neuroprotective
- Neuroprotective Effects
- Effects, Neuroprotective
|
Below are MeSH descriptors whose meaning is more general than "Neuroprotective Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuroprotective Agents".
This graph shows the total number of publications written about "Neuroprotective Agents" by people in UAMS Profiles by year, and whether "Neuroprotective Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 0 | 1 | | 2023 | 2 | 0 | 2 | | 2022 | 3 | 0 | 3 | | 2021 | 3 | 2 | 5 | | 2020 | 0 | 1 | 1 | | 2019 | 2 | 0 | 2 | | 2018 | 0 | 2 | 2 | | 2017 | 6 | 1 | 7 | | 2016 | 5 | 1 | 6 | | 2015 | 2 | 1 | 3 | | 2014 | 5 | 2 | 7 | | 2013 | 3 | 0 | 3 | | 2012 | 1 | 2 | 3 | | 2010 | 1 | 1 | 2 | | 2009 | 3 | 0 | 3 | | 2008 | 2 | 3 | 5 | | 2007 | 4 | 1 | 5 | | 2006 | 2 | 1 | 3 | | 2005 | 5 | 1 | 6 | | 2004 | 1 | 2 | 3 | | 2003 | 3 | 2 | 5 | | 2002 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuroprotective Agents" by people in Profiles over the past ten years.
-
Alqurashi MM, Al-Abbasi FA, Afzal M, Alghamdi AM, Zeyadi M, Sheikh RA, Alshehri S, Imam SS, Sayyed N, Kazmi I. Protective effect of sterubin against neurochemical and behavioral impairments in rotenone-induced Parkinson's disease. Braz J Med Biol Res. 2024; 57:e12829.
-
Kim W, Tripathi M, Kim C, Vardhineni S, Cha Y, Kandi SK, Feitosa M, Kholiya R, Sah E, Thakur A, Kim Y, Ko S, Bhatia K, Manohar S, Kong YB, Sindhu G, Kim YS, Cohen B, Rawat DS, Kim KS. An optimized Nurr1 agonist provides disease-modifying effects in Parkinson's disease models. Nat Commun. 2023 07 18; 14(1):4283.
-
Mahdi WA, AlGhamdi SA, Alghamdi AM, Imam SS, Alshehri S, Almaniea MA, Hajjar BM, Al-Abbasi FA, Sayyed N, Kazmi I. Neuroprotectant Effects of Hibiscetin in 3-Nitropropionic Acid-Induced Huntington's Disease via Subsiding Oxidative Stress and Modulating Monoamine Neurotransmitters in Rats Brain. Molecules. 2023 Feb 01; 28(3).
-
Xie E, Nadeem U, Xie B, D'Souza M, Sulakhe D, Skondra D. Using Computational Drug-Gene Analysis to Identify Novel Therapeutic Candidates for Retinal Neuroprotection. Int J Mol Sci. 2022 Oct 21; 23(20).
-
Ntagwabira F, Trujillo M, McElroy T, Brown T, Simmons P, Sykes D, Allen AR. Piperlongumine as a Neuro-Protectant in Chemotherapy Induced Cognitive Impairment. Int J Mol Sci. 2022 Feb 11; 23(4).
-
Alshehri S, Al-Abbasi FA, Ghoneim MM, Imam SS, Afzal M, Alharbi KS, Nadeem MS, Sayyed N, Kazmi I. Anti-Huntington's Effect of Butin in 3-Nitropropionic Acid-Treated Rats: Possible Mechanism of Action. Neurotox Res. 2022 Feb; 40(1):66-77.
-
Yu H, Liu X, Chen B, Vickstrom CR, Friedman V, Kelly TJ, Bai X, Zhao L, Hillard CJ, Liu QS. The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease. Cells. 2021 12 16; 10(12).
-
Fouda AY, Eldahshan W, Xu Z, Lemtalsi T, Shosha E, Zaidi SA, Abdelrahman AA, Cheng PN, Narayanan SP, Caldwell RW, Caldwell RB. Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury. Exp Neurol. 2022 02; 348:113923.
-
Bowroju SK, Penthala NR, Lakkaniga NR, Balasubramaniam M, Ayyadevara S, Shmookler Reis RJ, Crooks PA. Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease. Bioorg Med Chem. 2021 09 01; 45:116311.
-
Abdelmeguid NE, Khalil MIM, Elhabet R, Sultan AS, Salam SA. Combination of docosahexaenoic acid and Ginko biloba extract improves cognitive function and hippocampal tissue damages in a mouse model of Alzheimer's disease. J Chem Neuroanat. 2021 10; 116:101995.
-
Sadr AS, Eslahchi C, Ghassempour A, Kiaei M. In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis. Sci Rep. 2021 03 25; 11(1):6849.
-
Latham LE, Wang C, Patterson TA, Slikker W, Liu F. Neuroprotective Effects of Carnitine and Its Potential Application to Ameliorate Neurotoxicity. Chem Res Toxicol. 2021 05 17; 34(5):1208-1222.
-
Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Neuroinflammation. 2020 Nov 25; 17(1):354.
-
Culp WC, Onteddu SS, Brown A, Nalleballe K, Sharma R, Skinner RD, Witt T, Roberson PK, Marsh JD. Dodecafluoropentane Emulsion in Acute Ischemic Stroke: A Phase Ib/II Randomized and Controlled Dose-Escalation Trial. J Vasc Interv Radiol. 2019 Aug; 30(8):1244-1250.e1.
-
Eldahshan W, Ishrat T, Pillai B, Sayed MA, Alwhaibi A, Fouda AY, Ergul A, Fagan SC. Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study. Am J Physiol Heart Circ Physiol. 2019 05 01; 316(5):H1192-H1201.
-
McKinney SM, Magruder JT, Abramo TJ. An Update on Pediatric Stroke Protocol. Pediatr Emerg Care. 2018 Nov; 34(11):810-815.
-
Badanavalu MP, Srivatsan M. Nicotine is neuroprotective to neonatal neurons of sympathetic ganglion in rat. Auton Neurosci. 2019 01; 216:25-32.
-
Fouda AY, Newsome AS, Spellicy S, Waller JL, Zhi W, Hess DC, Ergul A, Edwards DJ, Fagan SC, Switzer JA. Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. Stroke. 2017 10; 48(10):2885-2887.
-
Wu KJ, Yu S, Lee JY, Hoffer B, Wang Y. Improving Neurorepair in Stroke Brain Through Endogenous Neurogenesis-Enhancing Drugs. Cell Transplant. 2017 09; 26(9):1596-1600.
-
Zhang YP, Brown RE, Zhang PC, Zhao YT, Ju XH, Song C. DHA, EPA and their combination at various ratios differently modulated A?25-35-induced neurotoxicity in SH-SY5Y cells. Prostaglandins Leukot Essent Fatty Acids. 2018 09; 136:85-94.
-
Mulkey SB, Ramakrishnaiah RH, McKinstry RC, Chang T, Mathur AM, Mayock DE, Van Meurs KP, Schaefer GB, Luo C, Bai S, Juul SE, Wu YW. Erythropoietin and Brain Magnetic Resonance Imaging Findings in Hypoxic-Ischemic Encephalopathy: Volume of Acute Brain Injury and 1-Year Neurodevelopmental Outcome. J Pediatr. 2017 07; 186:196-199.
-
Zhang Y, Jiao G, Song C, Gu S, Brown RE, Zhang J, Zhang P, Gagnon J, Locke S, Stefanova R, Pelletier C, Zhang Y, Lu H. An Extract from Shrimp Processing By-Products Protects SH-SY5Y Cells from Neurotoxicity Induced by A?25-35. Mar Drugs. 2017 Mar 22; 15(3).
-
Fouda AY, Pillai B, Dhandapani KM, Ergul A, Fagan SC. Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury. Eur J Pharmacol. 2017 Mar 15; 799:128-134.
-
Cippitelli A, Domi E, Ubaldi M, Douglas JC, Li HW, Demopulos G, Gaitanaris G, Roberto M, Drew PD, Kane CJM, Ciccocioppo R. Protection against alcohol-induced neuronal and cognitive damage by the PPAR? receptor agonist pioglitazone. Brain Behav Immun. 2017 Aug; 64:320-329.
-
Shaaban KA, Saunders MA, Zhang Y, Tran T, Elshahawi SI, Ponomareva LV, Wang X, Zhang J, Copley GC, Sunkara M, Kharel MK, Morris AJ, Hower JC, Tremblay MS, Prendergast MA, Thorson JS. Spoxazomicin D and Oxachelin C, Potent Neuroprotective Carboxamides from the Appalachian Coal Fire-Associated Isolate Streptomyces sp. RM-14-6. J Nat Prod. 2017 01 27; 80(1):2-11.
-
Zhang J, Hughes RR, Saunders MA, Elshahawi SI, Ponomareva LV, Zhang Y, Winchester SR, Scott SA, Sunkara M, Morris AJ, Prendergast MA, Shaaban KA, Thorson JS. Identification of Neuroprotective Spoxazomicin and Oxachelin Glycosides via Chemoenzymatic Glycosyl-Scanning. J Nat Prod. 2017 01 27; 80(1):12-18.
-
Arthur C, Song L, Culp W, Brown A, Borrelli M, Skinner R, Hendrickson H. Tissue Concentration of Dodecafluoropentane (DDFP) Following Repeated IV Administration in the New Zealand White Rabbit. AAPS J. 2017 03; 19(2):520-526.
-
Escalona-Vargas DI, Thagard AS, McGrail K, Napolitano PG, Magann EF, Lowery CL, Eswaran H. Observations of fetal brain activity via non-invasive magnetoencephalography following administration of magnesium sulfate for neuroprotection in preterm labor. Prenat Diagn. 2016 Oct; 36(10):982-984.
-
Sarkar S, Raymick J, Imam S. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci. 2016 Jun 08; 17(6).
-
Fouda AY, Alhusban A, Ishrat T, Pillai B, Eldahshan W, Waller JL, Ergul A, Fagan SC. Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke. Mol Neurobiol. 2017 01; 54(1):661-670.
-
Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, Deloach A, Calingasan NY, Beal MF, Kiaei M. Preferential PPAR-a activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum Mol Genet. 2016 Jan 15; 25(2):317-27.
-
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015 Aug; 14(8):795-803.
-
Culp WC, Brown AT, Lowery JD, Arthur MC, Roberson PK, Skinner RD. Dodecafluoropentane Emulsion Extends Window for tPA Therapy in a Rabbit Stroke Model. Mol Neurobiol. 2015 Oct; 52(2):979-84.
-
Fitzgerald RT, Ou X, Nix JS, Arthur MC, Brown AT, Skinner RD, Borrelli MJ, Culp WC. Dodecafluoropentane emulsion delays and reduces MRI markers of infarction in a rat stroke model: a preliminary report. Magn Reson Imaging. 2015 Feb; 33(2):236-9.
-
Sacktor N, Miyahara S, Evans S, Schifitto G, Cohen B, Haughey N, Drewes JL, Graham D, Zink MC, Anderson C, Nath A, Pardo CA, McCarthy S, Hosey L, Clifford D. Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol. 2014 Dec; 20(6):620-6.
-
Kemp SWP, Szynkaruk M, Stanoulis KN, Wood MD, Liu EH, Willand MP, Morlock L, Naidoo J, Williams NS, Ready JM, Mangano TJ, Beggs S, Salter MW, Gordon T, Pieper AA, Borschel GH. Pharmacologic rescue of motor and sensory function by the neuroprotective compound P7C3 following neonatal nerve injury. Neuroscience. 2015 Jan 22; 284:202-216.
-
Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, Cudkowicz ME, van den Berg LH, Mather J, Petzinger T, Archibald D. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep; 15(5-6):406-13.
-
Sarkar S, Chigurupati S, Raymick J, Mann D, Bowyer JF, Schmitt T, Beger RD, Hanig JP, Schmued LC, Paule MG. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model. Neurotoxicology. 2014 Sep; 44:250-62.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|